The Aporia · US FDA approves Mirum’s drug for rare bone disorder

The US FDA approved Mirum Pharmaceuticals’ drug Atebrioz on September 25 for treating fibrodysplasia ossificans progressiva (FOP), a rare bone disorder that affects about 300 people in the United States and 900 globally. Atebrioz, taken as a once-daily pill at a dose of 100 milligrams, blocks ALK2 protein to slow down abnormal bone formation outside the skeleton. Mirum plans to launch the drug in October but has not yet announced its price; analysts estimate it could cost around $750,000 annually and generate up to $150 million in peak sales worldwide.

Written by AI on 2026-09-28, from this article's own text only (the story summary below draws on all the coverage).

Story summary

On September 25, the US FDA approved Mirum Pharmaceuticals' drug Atebrioz for treating patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP), a rare bone disorder. Atebrioz is administered once daily at a dose of 100 milligrams, targeting the ALK2 protein which drives abnormal bone formation in FOP sufferers. The condition affects approximately 300 people in the US and around 900 globally.

Mirum plans to launch Atebrioz in October, with CEO Chris Peetz calling it a "game changer" for patients facing progressive bone accumulation. According to Citizens analyst Jonathan Wolleben's estimates, the drug could cost about US$750,000 annually and generate peak worldwide sales of roughly US$150 million.

Written for “FDA Approves Rare Bone Disorder Drug” on 2026-11-02, grounded in this article and the 0 other(s) covering the same event.

📰 FDA Approves Rare Bone Disorder Drug

Health · 1 article(s) covering the same event.

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Article leaning vs. publisher reliability

Source leaning vs. consistency

The Straits Times

2728 article(s) here · 1 carrying a prediction

🔮 How it plays out over the coming days or weeks could have a significant impact on next year's parliamentary election and potentially push Poland closer to US President Donald Trump and away from the European mainstream.

2026-11-02 · assertive framing · Explainer-What's behind Poland's constitutional crisis?

🔮 Houthi official Hamid Rizq posted a video, which Reuters could not immediately verify, of what he said were the group's fighters entering Souq al-Rabouh in Maqatirah district.

2026-11-02 · assertive framing · Yemen's Houthis advance to within 80 km of Aden, sources say

🔮 "The worst forecasts are coming true.

2026-11-02 · assertive framing · Seven migrants die in seas off Spain's Canary Islands

🔮 • Critics notably say CNews'agenda increasingly follows the lines taken by Marine Le Pen's far-right National Rally (RN), from which the channel could benefit if, as polls suggest, Le Pen wins the 2027 Presidential election and fulfils her promise to privatise public broadcasting, which CNews has long criticised.

2026-11-02 · mixed framing · French petition seeks to shut down Bollore's news channel CNews

🔮 Though no one would call him naive — he has served both as leader of the opposition against Prime Minister Benjamin Netanyahu and as a member of a unity cabinet under him — Herzog's soft-spoken manner can appear out of step with the times.

2026-11-02 · assertive framing · Isaac Herzog: the mild-mannered middleman in Israel's political brawl

🔮 We could not bear it.

2026-11-02 · assertive framing · Displaced Palestinians return to damaged Hebron quarter as Israeli troops withdraw

🔮 They saw an example of what reparatory justice could look like in practice.

2026-11-02 · mixed framing · As reparations debate grows, Caribbean campaigners point to one British family's example

🔮 On the eve of elections that will decide whether President Donald Trump’s Republican Party keeps control of Congress, voters’ minds are on the economy, with high and rising prices a key issue and many blaming Trump’s policies, specifically tariffs and the Iran war, for the nagging inflation.

2026-11-02 · assertive framing · American voters in a sour economic mood heading into midterm elections

🔮 US President Donald Trump’s threat to strike Iran again confronts America’s Gulf allies with a stark prospect: another war decided in Washington in which the US bases built to protect them could instead make them targets for harsh Iranian reprisal.

2026-11-02 · assertive framing · Trump's Iran threat renews Gulf fears of a war it didn't choose

🔮 Hungary's governing Tisza party will approve the president's nominee for chief prosecutor, Prime Minister Peter Magyar said on Monday, a significant step in Magyar's efforts to reshape public institutions after his April election victory.

2026-11-02 · assertive framing · Hungary's governing party backs nominee for chief prosecutor

Also by The Straits Times

Explainer-What's behind Poland's constitutional crisis?

2026-11-02 · The Straits Times

Yemen's Houthis advance to within 80 km of Aden, sources say

2026-11-02 · The Straits Times

French petition seeks to shut down Bollore's news channel CNews

2026-11-02 · The Straits Times

Seven migrants die in seas off Spain's Canary Islands

2026-11-02 · The Straits Times

Nothing else under this byline is closely related to this article, so these are simply their most recent.

All 2728 articles by The Straits Times →

The once-daily drug zilurgisertib, branded as Atebrioz, is approved for patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP), which causes muscles, tendons and ligaments to gradually transform into bone, restricting movement and leading to severe disability.

framing: assertive · carried by 1 article(s) · first seen 2026-09-28

🔮 Citizens analyst Jonathan Wolleben estimates Atebrioz could cost about US$750,000 (S$958,410) annually and generate roughly US$150 million in peak worldwide sales.

2026-09-28 · The Straits Times

US FDA approves Mirum’s drug for rare bone disorder · assertive framing

US FDA approves Mirum’s drug for rare bone disorder WASHINGTON - asserted

FDA → approve → disorder

The US FDA on Sept 25 approved Mirum Pharmaceuticals’ pill for a rare bone disorder, offering patients a new treatment option that can help slow the disease’s progression. asserted

that → approve → progression

muscles → brand → disability

Atebrioz blocks ALK2, a protein that is abnormally active in most patients with FOP and drives bone formation outside the skeleton. asserted

that → block → skeleton

The recommended dose is 100 milligrams. asserted

dose → recommend → ?

FOP is typically diagnosed in early childhood. asserted

FOP → diagnose → childhood

About 300 people in the US and 900 worldwide, according to Mirum, have the condition. uncertain

people → accord → condition

Mirum expects to launch the drug in October and plans to announce its price at the launch, chief executive officer Chris Peetz told Reuters. asserted

Peetz → expect → Reuters

“It is a game changer for patients to have a medicine like this that can really stop that progressive, endless accumulation of bone,” Peetz said. asserted

Peetz → have → bone

Citizens analyst Jonathan Wolleben estimates Atebrioz could cost about US$750,000 (S$958,410) annually and generate roughly US$150 million in peak worldwide sales. uncertain

Atebrioz → estimate → sales

Mirum had licensed the drug from Incyte earlier in 2026 for US$16 million upfront, along with potential milestone payments and sales royalties. asserted

Mirum → license → payments

The approval by the US Food and Drug Administration was based on a 63-patient study, in which Atebrioz significantly cut new bone formation compared to placebo at week 24. asserted

Atebrioz → base → week

Current treatment options for FOP include Ipsen’s oral drug Sohonos and Regeneron’s Pasatru, a monthly infusion. asserted

options → include → drug

Sohonos is approved for certain children and adults, while Pasatru is approved for adults. asserted

Pasatru → approve → adults

Wolleben said Atebrioz could become a preferred treatment because it combines oral dosing with strong efficacy and a favorable safety profile, offering greater convenience than Regeneron’s monthly infusion and potentially fewer safety concerns than Ipsen’s Sohonos. uncertain

it → say → Sohonos

US FDA approves Mirum’s drug for rare bone disorder

Quick Summary

AI analysis

Story

Compared with similar articles

Signals How these are calculated →

How this is being covered How these are calculated →

Publisher

Who wrote this

Topics

Subjects

Narrative

Claims (15 extracted, 3 hedged)